Control Bionics Ltd (ASX: CBL) is pleased to announce the appointment of Jeremy Steele as Chief Executive Officer and a member of the board, effective from 19 January 2023. Mr. Steele brings over 25 years of global corporate experience across a wide range of industries including healthcare, software, financial services and retail in senior roles, including most recently as Executive Chairman and subsequently CEO of CardioScan.
Mr. Steele will initially be based in his current location of Singapore, in the midst of our key Australasian markets and may transition to the CBL office in Melbourne over time. CBL Chairman, Rodger Hawke, stated that the Board of CBL was excited by Jeremy’s appointment and was looking forward to working with him and the CBL executive team to drive the CBL strategy in 2023 and beyond.
“CBL is at an exciting inflection point with improved growth in our core markets and a number of new product innovations under development, and we are delighted to have Jeremy join our team to drive the continued success of our business. We are confident that his business acumen, experience and enthusiasm will drive new value creation opportunities for the business, our shareholders and our people.” said Mr. Hawke.
Mr. Steele commented on his appointment:
“CBL has all the ingredients for success including the unique NeuroNode technology, great people and a pipeline of new opportunities and I am excited about leading the company to a successful future, delivering value to our shareholders, and a great place to work for our people.”
Upon the appointment of Mr. Steele, Rob Wong will resign as director. The Board would like to acknowledge the contribution of Mr. Wong who led the company since January 2017, until his recent resignation due to an ongoing medical condition.
The Board also wishes to acknowledge founder and interim CEO, Peter Ford for his leadership of the company in the period up to the appointment of Mr. Steele.
For more information, see our For Investors site.